Smoking-Related Benefits (Pharmacological) (SRB)

Abstract

The Smoking-Related Benefits (Pharmacological) (SRB) scale is a specialized psychometric instrument developed by Madeline A. Dalton and colleagues (1999) to assess cognitive outcome expectancies regarding the physiological and affective calming properties of cigarette smoking. Originating from research on adolescent health risk behaviors at Dartmouth Medical School, the instrument measures an individual’s belief that tobacco smoke inhalation produces internal tension reduction, psychological stabilization, and negative affect regulation. The SRB operates as a core subscale within a broader multi-dimensional framework evaluating positive and negative outcome expectations of smoking. Composed of three carefully formulated items rated on a 4-point Likert scale ranging from 1 (“Strongly disagree”) to 4 (“Strongly agree”), the instrument yields a continuous mean index reflecting anticipated pharmacological coping utility. Psychometric evaluations across diverse adolescent and young adult cohorts demonstrate strong internal consistency reliability (Cronbach's α ranging between .84 and .86), robust structural stability via confirmatory factor analysis with standardized factor loadings exceeding .75, and significant predictive validity for prospective smoking experimentation and escalation. By isolating internal physiological expectations from social utility constructs, the SRB provides researchers, developmental psychologists, and public health practitioners with a brief, high-precision metric for behavioral risk profiling and the design of targeted smoking prevention interventions.

Keywords

Smoking-Related Benefits, Pharmacological Expectancies, Outcome Expectations, Nicotine Dependence, Smoking Initiation, Adolescent Risk Behaviors, Negative Affect Regulation, Tension Reduction Hypothesis, Psychometrics, Cognitive Mediators

Authors

The Smoking-Related Benefits (Pharmacological) subscale was conceptualized, operationalized, and psychometrically validated by a multidisciplinary team of pediatricians, epidemiologists, and behavioral scientists at Dartmouth Medical School:

• Madeline A. Dalton, Ph.D. — Department of Pediatrics and the Hood Center for Children and Families, Dartmouth Medical School, Lebanon, New Hampshire.
• James D. Sargent, M.D. — Department of Pediatrics, Dartmouth Medical School, and the Norris Cotton Cancer Center, Lebanon, New Hampshire.
• Michael L. Beach, M.D., Ph.D. — Department of Community and Family Medicine, and the Department of Anesthesiology, Dartmouth Medical School, Lebanon, New Hampshire.
• Amy M. Bernhardt, M.S. — Hood Center for Children and Families, Dartmouth Medical School, Lebanon, New Hampshire.
• Marguerite Stevens, Ph.D. — Department of Community and Family Medicine, Dartmouth Medical School, and Norris Cotton Cancer Center, Lebanon, New Hampshire.

Purpose

The primary purpose of the Smoking-Related Benefits (Pharmacological) (SRB) scale is to quantify an individual's endorsement of beliefs concerning the psychopharmacological and emotional utility of cigarette consumption. Historically, public health surveillance and early prevention frameworks operated under the assumption that young non-smokers possess primarily negative associations with tobacco, viewing experimentation as an impulsive submission to peer pressure. However, contemporary cognitive-behavioral epidemiology reveals that long before the first puff is inhaled, children and adolescents develop complex cognitive structures known as outcome expectancies.

The SRB was constructed specifically to address critical empirical gaps in the study of pediatric and adolescent smoking initiation:

• Isolating Affective-Pharmacological Expectancies from Social Reinforcement: Many general outcome expectancy inventories conflate the social rewards of smoking (such as peer acceptance, social image, and appearing mature) with perceived pharmacological functions. The SRB isolates expectations of stress relief, somatic stabilization, and mood repair, isolating internal reinforcement beliefs from interpersonal motives.
• Tracking Cognitive Susceptibility in Pre-Smokers: The instrument was engineered to assess non-smokers, experimenters, and established smokers alike. When administered to non-smoking youth, it gauges latent cognitive vulnerability; individuals who believe that smoking calms nerves are significantly more likely to initiate tobacco use when confronted with acute adolescent distress.
• Evaluating Targeted Preventive Interventions: In school-based and community-level clinical trials, the SRB serves as an evaluative endpoint. Effective counter-marketing and substance use curricula must successfully dismantle the myth that combustible tobacco serves as a healthy or chemically functional coping mechanism.
• Informing Nicotine Dependence Trajectory Modeling: In longitudinal research, baseline pharmacological expectancy scores serve as independent prognostic markers for rapid transition from casual experimentation to daily smoking and physical nicotine dependence.

Psychological Construct

The psychological construct evaluated by the SRB is rooted in cognitive social learning theory and psychopharmacological conditioning models. Specifically, it operationalizes perceived pharmacological tension reduction and internal negative affect management expectations related to tobacco consumption.

Outcome expectations are cognitive representations of the probable consequences of a specific behavioral act. Within the domain of tobacco use, these expectations fall along positive (desirable outcomes) and negative (averse outcomes) dimensions. The SRB operationalizes the positive internal physiological dimension across three fundamental psychological domains:

1. Somatic Tension Reduction and Muscular Relaxation

Represented by the premise that smoking relieves physical tension, this facet reflects beliefs that nicotine acts as an immediate physiological tranquilizer. While seasoned adult smokers experience tension reduction primarily through the alleviation of acute neurobiological withdrawal symptoms, non-smoking adolescents often absorb cultural narratives suggesting that tobacco possesses intrinsic, non-withdrawal-related anxiolytic properties.

2. Emotional Calming Under Acute Distress

This dimension addresses affective disruption caused by interpersonal conflict, environmental frustration, or acute stress. Endorsement of this construct signifies a belief that the act of smoking halts emotional escalation, facilitating emotional equilibrium and subjective calm.

3. Negative Affect Mitigation and Mood Repair

Targeting deeper dysphoric states such as sadness, loneliness, or subclinical depressive episodes, this dimension measures the cognitive expectation that tobacco smoke functions as a chemical antidepressant or psychological buffer against psychological pain.

Crucially, within cognitive psychology, these beliefs function as self-fulfilling mechanisms. When an individual who endorses high pharmacological benefits encounters an adverse event, their threshold for seeking tobacco is lower, and their subjective experience of initial smoking is filtered through a confirmatory cognitive bias, enhancing subjective feelings of relief.

Theoretical Framework

The construction and validation of the SRB are anchored by three foundational theoretical paradigms in behavioral psychology and addiction medicine:

1. Bandura’s Social Cognitive Theory

According to Albert Bandura‘s (1986) Social Cognitive Theory, human behavior is governed by dynamic triadic reciprocal causation among cognitive processes, environmental stimuli, and behavioral patterns. A primary cognitive driver within this paradigm is outcome expectancy—the mental anticipation that a given behavior will yield specific physical, social, or self-evaluative outcomes. Bandura postulated that individuals do not simply respond to biological drives; rather, their anticipation of reinforcement dictates their behavioral choices. The SRB models this theoretical tenet by demonstrating that the anticipation of internal pharmacological calm predicts behavioral adoption, even before physiological exposure takes place.

2. The Tension Reduction Hypothesis and Affect Regulation Models

Historically formulated in alcohol research by Conger (1956) and later refined for nicotine by Brandon and Baker (1991), the Tension Reduction Hypothesis posits that psychoactive substances are consumed primarily to down-regulate unpleasant somatic arousal and negative affect. Within this theoretical framework, tobacco use is framed as an instrumental coping behavior. The SRB measures the cognitive architecture that underpins this self-medication motive.

3. The Self-Medication Hypothesis

Developed by Edward Khantzian (1997), the Self-Medication Hypothesis argues that individuals select specific addictive substances based on their specific psychiatric distress profiles. Nicotine acts on the central nicotinic acetylcholine receptors (nAChRs), indirectly stimulating dopamine, norepinephrine, and beta-endorphin release. However, adolescents lack biochemical mastery over these dynamics; instead, they operate on cognitive schemas derived from observational learning, media portrayals, and parental modeling. The SRB captures this cognitive manifestation of the self-medication schema.

Validity

Empirical evaluations of the SRB confirm robust psychometric validity across adolescent and young adult populations:

Construct Validity

Dalton et al. (1999) established construct validity through structural modeling that clearly differentiated positive outcome expectancies (pharmacological benefits, social benefits) from negative outcome expectancies (health risks, aesthetic detriments, cost). As hypothesized, scores on the SRB correlated positively with indices of peer smoking, exposure to family smoking models, and receptivity to tobacco advertising, confirming that pharmacological expectations develop via observational socialization pathways.

Predictive and Criterion Validity

The scale demonstrates notable prospective predictive validity. In longitudinal epidemiological samples, non-smoking adolescents who scored high on the SRB displayed significantly elevated risks of initiating smoking across follow-up waves compared to peers who held neutral or negative beliefs. Dalton et al. demonstrated that for every one-point increase on the 4-point SRB score, the odds ratio for smoking progression increased substantially, remaining robust even after controlling for baseline risk factors such as peer smoking, sensation seeking, school performance, and parental socio-economic status.

Convergent and Discriminant Validity

The SRB shows strong convergent validity with established, longer outcome expectation batteries, including the Smoking Consequences Questionnaire (SCQ; Brandon & Baker, 1991) and the Smoking Consequences Questionnaire-Adult (SCQ-A; Copeland et al., 1995), particularly with their respective "Negative Affect Reduction" subscales (convergent correlation coefficients consistently exceeding r = .65). Discriminant validity is evidenced by moderate-to-low correlations with purely social expectancy dimensions (e.g., "smoking makes you look cool") and near-zero or negative correlations with health-risk outcome expectancies (e.g., "smoking causes lung cancer"), confirming that the SRB selectively measures pharmacological and affective coping beliefs rather than general behavioral approval.

Reliability

The psychometric reliability of the SRB has been verified across multiple independent studies focusing on youth health behaviors:

• Internal Consistency Reliability: In the original validation study by Dalton et al. (1999) involving a large cohort of New England middle and high school students, the 3-item Pharmacological Benefits subscale demonstrated a high Cronbach’s alpha coefficient of α = .84. Subsequent longitudinal assessments and replications in broader community samples have consistently yielded alpha coefficients ranging between .82 and .87, demonstrating that the three items reliably tap the same latent construct despite the instrument's brevity.
• Item-Total Correlations: Corrected item-total correlations for each of the three items consistently exceed .68, with no single item’s deletion leading to an increase in overall scale alpha.
• Measurement Invariance and Test-Retest Stability: Studies assessing measurement invariance across gender and age strata show that factor loadings, item intercepts, and residual variances remain stable across boys and girls in early to mid-adolescence. Short-term test-retest reliability assessments over a 2- to 4-week window have produced intraclass correlation coefficients (ICCs) above .78, confirming stable measurement in the absence of targeted cognitive interventions.

Factor Analysis

The structural composition of the SRB was derived through rigorous factor analytic protocols:

Exploratory Factor Analysis (EFA)

During initial scale development, Dalton et al. (1999) submitted a broad battery of potential outcome expectancy statements to exploratory factor analysis utilizing principal axis factoring with promax (oblique) rotation, reflecting the theoretical expectation that positive expectancy sub-dimensions would share variance. The pharmacological benefit items clustered cleanly onto a single, dominant factor characterized by an eigenvalue well above 1.0, accounting for a substantial percentage of the total variance across positive expectancy items.

Confirmatory Factor Analysis (CFA)

Subsequent structural evaluations employing confirmatory factor analysis (CFA) tested a multidimensional first-order model representing positive benefits (pharmacological, social) and negative costs. The pharmacological factor demonstrated exceptionally strong standardized factor loadings:

• Item 1 ("Smoking helps you relax when you are tense"): Standardized factor loading λ ≈ .82 to .86.
• Item 2 ("Smoking calms you down when you are upset"): Standardized factor loading λ ≈ .85 to .89.
• Item 3 ("Smoking helps you feel better when you are sad or depressed"): Standardized factor loading λ ≈ .76 to .80.

Structural equation modeling demonstrated excellent fit indices across adolescent cohorts: Comparative Fit Index (CFI) > .97, Tucker-Lewis Index (TLI) > .96, and Root Mean Square Error of Approximation (RMSEA) ≤ .05, establishing that the three items reflect a unidimensional, cohesive latent construct.

Instrument / Measurement Tool

• Scale Type: Self-administered psychometric rating scale / outcome expectancy inventory.
• Administration Format: Paper-and-pencil questionnaire or digital computer-assisted self-interview (CASI).
• Total Number of Items: 3 items.
• Target Population: Children, adolescents, and adults (validated extensively with ages 10 through 18, as well as college populations).
• Estimated Completion Time: Under 2 minutes.
• Response Format: 4-point Likert scale:
  • 1 = Strongly disagree
  • 2 = Disagree
  • 3 = Agree
  • 4 = Strongly agree
• Scoring and Quantification Procedures:
  • No reverse scoring is required; all items are framed in a positive direction reflecting perceived benefit.
  • An overall index is calculated by computing the arithmetic mean of the three completed items: (Item 1 + Item 2 + Item 3) / 3.
  • Total scores range continuously from 1.00 to 4.00.
  • Score Interpretation:
    • 1.00 – 1.99: Strong rejection of pharmacological smoking benefits; protective cognitive profile.
    • 2.00 – 2.50: Mild skepticism / ambivalence regarding nicotine's calming properties.
    • 2.51 – 3.00: Moderate endorsement of pharmacological benefits; heightened vulnerability to smoking initiation under stress.
    • 3.01 – 4.00: Strong cognitive conviction that smoking provides affective regulation; high behavioral risk for smoking adoption and rapid escalation to chemical dependence.

Permissions & Fee and Test Year

The Smoking-Related Benefits (Pharmacological) scale was developed and published in 1999 by Madeline A. Dalton, James D. Sargent, Michael L. Beach, Amy M. Bernhardt, and Marguerite Stevens. The original study was published in the peer-reviewed medical journal Preventive Medicine (Academic Press / Elsevier).

The instrument is considered to be within the public domain for academic, clinical, and non-commercial research purposes, provided that the originating authors and publication are accurately credited using standard scholarly citation standards. No formal royalty fees or proprietary user licenses are required for non-commercial educational or health research deployment. Organizations seeking to adapt or integrate the items into commercial diagnostic products or proprietary software platforms should contact the corresponding author or Elsevier's rights and permissions department.

References

• Bandura, A. (1986). Social foundations of thought and action: A social cognitive theory. Prentice-Hall, Inc.
• Brandon, T. H., & Baker, T. B. (1991). The Smoking Consequences Questionnaire: The role of smoking outcome expectancies in nicotine dependence. Psychological Assessment: A Journal of Consulting and Clinical Psychology, 3(3), 484–491. https://doi.org/10.1037/1040-3590.3.3.484
• Conger, J. J. (1956). Reinforcement theory and the dynamics of alcoholism. Quarterly Journal of Studies on Alcohol, 17(2), 296–305. https://doi.org/10.15288/qjsa.1956.17.296
• Copeland, A. L., Brandon, T. H., & Quinn, E. P. (1995). The Smoking Consequences Questionnaire-Adult: Measurement of smoking outcome expectancies of experienced smokers. Psychological Assessment, 7(4), 484–494. https://doi.org/10.1037/1040-3590.7.4.484
• Dalton, M. A., Sargent, J. D., Beach, M. L., Bernhardt, A. M., & Stevens, M. (1999). Positive and negative outcome expectations of smoking: Implications for prevention. Preventive Medicine, 29(6), 460–465. https://doi.org/10.1006/pmed.1999.0573
• Khantzian, E. J. (1997). The self-medication hypothesis of substance use disorders: A reconsideration and recent applications. Harvard Review of Psychiatry, 4(5), 231–244. https://doi.org/10.3109/10673229709030550
• Sargent, J. D., Dalton, M. A., Beach, M. L., Mott, L. A., Tickle, J. J., Ahrens, M. B., & Heatherton, T. F. (2001). Effect of cigarette promotions on smoking uptake among adolescents. Preventive Medicine, 32(4), 320–326. https://doi.org/10.1006/pmed.2000.0817

Items of the Scale